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Purpose of the study
To compare the lipometabolic profiles of three double-
boosted protease inhibitor (PI) regimens at standard
dose, containing saquinavir and ritonavir in combination
with lopinavir (LOPSAQ), atazanavir (ATSAQ) or fosam-
prenavir (FOSAQ) in HIV-positive patients, treated with-
out reverse transcriptase inhibitors (RTI).
Methods
Comparative cohort analysis on 173 patients receiving
LOPSAQ, ATSAQ or FOSAQ as only antiretroviral therapy
(ART). Total cholesterol and triglycerides were measured
at baseline (BL) and in the course over 48 weeks after ini-
tiation of a ritonavir-boosted double PI regimen. High-
density-lipoprotein (HDL) and low-density-lipoprotein
(LDL) were measured after an overnight fast.
Summary of results
Median baseline characteristics were a patient age of 42
years, male gender (n = 139; 80.4%) and 10.1 years from
first HIV-positive test. 158 patients were ART-experienced
and received a boosted double PI regimen due to previous
RTI-resistance and/or toxicity. Among these, 68 patients
previously had a structured treatment interruption and 90
patients have been treated with a PI-sparing ART regimen;
15 patients were ART-naïve. Differences for metabolic
parameters between groups were not significant. Fifty-
eight out of 173 patients received a lipid-lowering agent
(LLA) (LOPSAQ n = 42, ATSAQ n = 11, FOSAQ n = 5) and
seven (4%) were initiated on a new LLA during the study.
Total cholesterol significantly increased over 48 weeks for
all groups: 166 mg/dL to 213 mg/dL (LOPSAQ), 168 mg/
dL to 216 mg/dL (ATSAQ) and 161 mg/dl to 235 mg/dl
(FOSAQ) after 48 weeks (for all, p < 0.01; ITT-analysis),
whereas median triglyceride levels significantly increased
only for the LOPSAQ-group (195 mg/dl to 283 mg/dl; p <
0.01), but not for the other two groups (ATSAQ: 161 mg/
dL to 202 mg/dL, p = 0.2; FOSAQ: 130 mg/dl to 220 mg/
dl, p = 0.6). HDL- and LDL-cholesterol increased non-sig-
nificantly in all groups. See Figure 1.
Conclusion
After 48 weeks on a double-boosted PI regimen, all three
patient groups showed significant increases in total cho-
lesterol. The increase in triglyceride levels was only signif-
icant for LOPSAQ, but not for ATSAQ or FOSAQ. Overall,
<5% required a new LLA-therapy during the first 48
weeks. HDL- and LDL-cholesterol increases were not sig-
nificant. The cardiovascular impact of these lipometabolic
interferences requires further investigations.
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